@文章{信息:doi/10.2196/27588，作者=“Mujcic, Ajla和Blankers, Matthijs和Boon, Brigitte和verdoneck -de Leeuw, Irma M和Smit, Filip和van Laar, Margriet和Engels, Rutger”，标题=“癌症幸存者数字戒烟干预的有效性，成本-效益和成本-效用:一项实用的随机对照试验的健康经济评价与结果”，期刊=“J Med Internet Res”，年=“2022”，月=“3”，日=“17”，卷=“24”，数=“3”，页=“e27588”，关键词=“戒烟;癌症幸存者;有效性;成本效益;背景:戒烟(SC)干预措施可能有助于更好的治疗结果和癌症幸存者的总体福祉。目的:本研究旨在评估数字交互式SC干预与非交互式基于web的癌症幸存者信息手册的有效性、成本效益和成本效用。方法:健康经济评估与实用的2臂平行组随机对照试验一起进行，并在3、6和12个月进行随访。该研究于2016年11月至2019年9月在荷兰通过互联网进行。这些参与者都是有意戒烟的荷兰成年吸烟癌症幸存者。 In total, 165 participants were included and analyzed: 83 (50.3{\%}) in the MyCourse group and 82 (49.7{\%}) in the control group. In the intervention group, participants had access to a newly developed, digital, minimally guided SC intervention (MyCourse-Quit Smoking). Control group participants received a noninteractive web-based information brochure on SC. Both groups received unrestricted access to usual care. The primary outcome was self-reported 7-day smoking abstinence at the 6-month follow-up. Secondary outcomes were quality-adjusted life years gained, number of cigarettes smoked, nicotine dependence, and treatment satisfaction. For the health economic evaluation, intervention costs, health care costs, and costs stemming from productivity losses were assessed over a 12-month horizon. Results: At the 6-month follow-up, the quit rates were 28{\%} (23/83) and 26{\%} (21/82) in the MyCourse and control groups, respectively (odds ratio 0.47, 95{\%} CI 0.03-7.86; P=.60). In both groups, nicotine dependence scores were reduced at 12 months, and the number of smoked cigarettes was reduced by approximately half. The number of cigarettes decreased more over time, and the MyCourse group demonstrated a significantly greater reduction at the 12-month follow-up (incidence rate ratio 0.87; 95{\%} CI 0.76-1.00; P=.04). Intervention costs were estimated at US {\$}193 per participant for the MyCourse group and US {\$}74 for the control group. The mean per-participant societal costs were US {\$}25,329 (SD US {\$}29,137) and US {\$}21,836 (SD US {\$}25,792), respectively. In the cost-utility analysis, MyCourse was not preferred over the control group from a societal perspective. With smoking behavior as the outcome, the MyCourse group led to marginally better results per reduced pack-year against higher societal costs, with a mean incremental cost-effectiveness ratio of US {\$}52,067 (95{\%} CI US {\$}32,515-US {\$}81,346). Conclusions: At 6 months, there was no evidence of a differential effect on cessation rates; in both groups, approximately a quarter of the cancer survivors quit smoking and their number of cigarettes smoked was reduced by half. At 12 months, the MyCourse intervention led to a greater reduction in the number of smoked cigarettes, albeit at higher costs than for the control group. No evidence was found for a differential effect on quality-adjusted life years. Trial Registration: The Netherlands Trial Register NTR6011; https://www.trialregister.nl/trial/5434 International Registered Report Identifier (IRRID): RR2-10.1186/s12885-018-4206-z ", issn="1438-8871", doi="10.2196/27588", url="//www.mybigtv.com/2022/3/e27588", url="https://doi.org/10.2196/27588", url="http://www.ncbi.nlm.nih.gov/pubmed/35297777" }